Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?

April 26, 2017agonist fracture increase prostate cancer risk therapy

0

Posted

Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?

1 Answer

0

Posted

Review Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. [Clin Ther. 2006] Review Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.Moreau JP, Delavault P, Blumberg J. Clin Ther. 2006 Oct; 28(10):1485-508. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. [Urology. 2008] Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.Bong GW, Clarke HS Jr, Hancock WC, Keane TE. Urology. 2008 Jun; 71(6):1177-80. Epub 2008 Feb 15. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. [Scand J Urol Nephrol.